Bristol Myers Squibb is taking a broom to the bottom of its pipeline, axing at least nine assets including one phase 2 med being studied in a variety of solid tumors. The cleanout was disclosed in the ...
As the TIGIT class gets closer to finally seeing clinical success, Bristol Myers Squibb is trimming one of its candidates. The company disclosed development of a phase 2 anti-TIGIT is ending as part ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results